Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon

https://doi.org/10.1016/S0002-9610(99)80071-3Get rights and content

Background

Genetic mutations involving onccgenes and tumor-suppressor genes occur in carcinogenesis, and may affect biologic behavior of neoplasms. In this study, we analyzed the prognostic value of mutational analysis in Colon carcinoma.

Patients and methods

Archival pathology specimens from 70 consecutive patients, resected for stage III colon carcinoma, were analyzed for point mutations by amplification and direct sequencing of exons from the K-ras-2 and the TP53 genes (topographic genotyping). Mutations were compared with adverse histopathologic features (poor differentiation, vascular and lymphatic invasion, mucin production) as prognostic markers.

Results

Five-year survival was 75% in patients with nonmutated lesions, significantly lower (21%) with TP53 mutations (P = 0.01), and intermediate with K-ras-2 only (45%) or both K-ras-2 and TP53 mutations (36%). A TP53 mutation carried the highest relative risk of death (2.39; 95% confidence interval, 1.29 to 4.42; P = 0.006). There was an additive effect on the risk of death between TP53 mutations and adverse histopathologic features.

Conclusions

The information derived from mutational analysis is creating new prognostic variables that may play a role in the choice of therapy for colorectal carcinoma.

References (26)

  • YoungJ et al.

    Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers

    Oncogene

    (1994)
  • BosariS et al.

    Cytoplasmic accumulation of p53 protein: an independent prognostic indicator of colorectal adenocarcinomas

    J Natl Cancer Inst.

    (1994)
  • FinkelsteinSD et al.

    Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis

    Arch Surg.

    (1993)
  • Cited by (76)

    • Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13

      2015, Genomics
      Citation Excerpt :

      However, monoclonal anti-EGFR antibodies are sometimes ineffective against metastasis derived from CRC even when the primary CRC has wild-type K-ras, which might be due to differences between primary CRCs and the corresponding metastatic tumors with regard to K-ras mutational status. Some studies of the relationship between K-ras gene mutations and various clinicopathological characteristics have been conducted, but the results remain inconclusive [9–12]. To clarify the relationship between K-ras gene mutations and the prognosis for patients with colorectal cancer, it was necessary to perform a systematic review and meta-analysis of the published studies to derive a more precise estimation [13], where the associations of the prognostic significance for patients with mutations at codon 12 become nonsignificant after adjusting for the effect of publication bias, while K-ras mutations at codon 13 are associated with poorer overall survival.

    • Mutant KRAS, chromosomal instability and prognosis in colorectal cancer

      2005, Biochimica et Biophysica Acta - Reviews on Cancer
    • Predictive and prognostic genetic markers in colorectal cancer

      2004, Seminars in Colon and Rectal Surgery
    • The genetics of sporadic colon cancer

      2004, Seminars in Colon and Rectal Surgery
    • Colorectal cancer: Prognostic molecular markers

      2004, Gastroenterologie Clinique et Biologique
    View all citing articles on Scopus
    View full text